Literature DB >> 33525642

Comprehensive Study of Atorvastatin Nanostructured Lipid Carriers through Multivariate Conceptualization and Optimization.

Heba A Ghanem1, Ali M Nasr2,3, Tamer H Hassan4, Mahmoud M Elkhoudary5, Reem Alshaman6, Abdullah Alattar6, Shadeed Gad4.   

Abstract

The aim of the current study is to establish a comprehensive experimental design for the screening and optimization of Atorvastatin-loaded nanostructured lipid carriers (AT-NLCs). Initially, combined D-optimal screening design was applied to find the most significant factors affecting AT-NLCs properties. The studied variables included mixtures of solid and liquid lipids, the solid/liquid lipid ratio, surfactant type and concentration, homogenization speed as well as sonication time. Then, the variables homogenization speed (A), the ratio of solid lipid/liquid lipid (B), and concentration of the surfactant (C) were optimized using a central composite design. Particle size, polydispersity index, zeta potential, and entrapment efficiency were chosen as dependent responses. The optimized AT-NLCs demonstrated a nanometric size (83.80 ± 1.13 nm), Polydispersity Index (0.38 ± 0.02), surface charge (-29.65 ± 0.65 mV), and high drug incorporation (93.1 ± 0.04%). Fourier Transform Infrared Spectroscopy (FTIR) analysis showed no chemical interaction between Atorvastatin and the lipid mixture. Differential Scanning Calorimetry (DSC) analysis of the AT-NLCs suggested the transformation of Atorvastatin crystal into an amorphous state. Administration of the optimized AT-NLCs led to a significant reduction (p < 0.001) in serum levels of rats' total cholesterol, triglycerides, and low-density lipoproteins. This change was histologically validated by reducing the relevant steatosis of the liver.

Entities:  

Keywords:  atorvastatin; central composite design; combined D-optimal screening design; hyperlipidemia; nano-structured lipid carriers

Year:  2021        PMID: 33525642      PMCID: PMC7911144          DOI: 10.3390/pharmaceutics13020178

Source DB:  PubMed          Journal:  Pharmaceutics        ISSN: 1999-4923            Impact factor:   6.321


  39 in total

1.  Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration.

Authors:  Aihua Song; Xiaoshu Zhang; Yanting Li; Xinjuan Mao; Fei Han
Journal:  Drug Dev Ind Pharm       Date:  2016-01-20       Impact factor: 3.225

2.  Development of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application.

Authors:  Petra O Nnamani; Steffi Hansen; Maike Windbergs; Claus-Michael Lehr
Journal:  Int J Pharm       Date:  2014-10-05       Impact factor: 5.875

3.  Formulation and characterization of novel nanostructured lipid carriers made from beeswax, propolis wax and pomegranate seed oil.

Authors:  Yasamin Soleimanian; Sayed Amir Hossein Goli; Jaleh Varshosaz; Sayed Mohammad Sahafi
Journal:  Food Chem       Date:  2017-10-05       Impact factor: 7.514

4.  Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in hyperlipidemia animal model.

Authors:  Syed Zaki Husain Rizvi; Fawad Ali Shah; Namrah Khan; Iftikhar Muhammad; Khan Hashim Ali; Muhammad Mohsin Ansari; Fakhar Ud Din; Omer Salman Qureshi; Kyoung-Won Kim; Yeong-Hwan Choe; Jin-Ki Kim; Alam Zeb
Journal:  Int J Pharm       Date:  2019-02-10       Impact factor: 5.875

5.  Enhancement of oral bioavailability of atorvastatin calcium by self-emulsifying drug delivery systems (SEDDS).

Authors:  Pawan J Kadu; Sachin S Kushare; Dhaval D Thacker; Surendra G Gattani
Journal:  Pharm Dev Technol       Date:  2010-01-20       Impact factor: 3.133

6.  Development and optimization of transferrin-conjugated nanostructured lipid carriers for brain delivery of paclitaxel using Box-Behnken design.

Authors:  Jaber Emami; Mahboubeh Rezazadeh; Hojjat Sadeghi; Khashayar Khadivar
Journal:  Pharm Dev Technol       Date:  2016-09-30       Impact factor: 3.133

7.  Optimisation of chloroquine phosphate loaded nanostructured lipid carriers using Box-Behnken design and its antimalarial efficacy.

Authors:  Uday Krishna Baruah; Kuppusamy Gowthamarajan; Vanka Ravisankar; Veera Venkata Satyanarayana Reddy Karri; Praveen Kumar Simhadri; Vineeta Singh
Journal:  J Drug Target       Date:  2017-10-23       Impact factor: 5.121

8.  Quality by Design for the Development and Analysis of Enhanced In-Situ Forming Vesicles for the Improvement of the Bioavailability of Fexofenadine HCl in Vitro and in Vivo.

Authors:  Ali M Nasr; Mona K Qushawy; Mahmoud M Elkhoudary; Aya Y Gawish; Sameh S Elhady; Shady A Swidan
Journal:  Pharmaceutics       Date:  2020-04-29       Impact factor: 6.321

9.  Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides.

Authors:  Gang Yang; Feihua Wu; Minyan Chen; Jian Jin; Rong Wang; Yongfang Yuan
Journal:  Int J Nanomedicine       Date:  2019-04-01

10.  Oral Bioavailability Enhancement of Raloxifene with Nanostructured Lipid Carriers.

Authors:  Aditya Murthy; Punna Rao Ravi; Himanshu Kathuria; Shrinivas Malekar
Journal:  Nanomaterials (Basel)       Date:  2020-05-31       Impact factor: 5.076

View more
  3 in total

1.  Hypolipidemic Activity of Olive Oil-Based Nanostructured Lipid Carrier Containing Atorvastatin.

Authors:  Heba S Elsewedy; Tamer M Shehata; Mervt M Almostafa; Wafaa E Soliman
Journal:  Nanomaterials (Basel)       Date:  2022-06-23       Impact factor: 5.719

2.  Development and Optimization of Nigella sativa Nanoemulsion Loaded with Pioglitazone for Hypoglycemic Effect.

Authors:  Tamer M Shehata; Mervt M Almostafa; Heba S Elsewedy
Journal:  Polymers (Basel)       Date:  2022-07-26       Impact factor: 4.967

3.  Fabrication of nanostructured lipid carriers ocugel for enhancing Loratadine used in treatment of COVID-19 related symptoms: statistical optimization, in-vitro, ex-vivo, and in-vivo studies evaluation.

Authors:  Rehab Abdelmonem; Inas Essam Ibrahim Al-Samadi; Rasha M El Nashar; Bhaskara R Jasti; Mohamed A El-Nabarawi
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.